Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Glybera

    - PMLiVE

    uniQure’s investigational gene therapy shown to slow Huntington’s disease progression

    The neurodegenerative disorder affects approximately 70,000 people in Europe and the US

    - PMLiVE

    FDA removes clinical hold on uniQure’s haemophilia gene therapy

    Clinical hold placed following a case of hepatocellular carcinoma in a patient in the trial

    - PMLiVE

    New results back Sangamo, UniQure haemophilia gene therapies

    Encouraging results for firms in four-way race

    - PMLiVE

    UniQure gets speedy US review for Huntington’s gene therapy

    Pioneer gaining momentum again

    - PMLiVE

    UniQure edges closer to haemophilia B gene therapy OK

    The candidate could free patients from regulator injections of FIX products

    - PMLiVE

    UniQure cleared to start Huntington gene therapy trial

    AMT-130 becomes the first AAV-based therapy approved for trials in Huntington’s disease

    - PMLiVE

    UniQure skyrockets on haemophilia B gene therapy data

    Competition with Pfizer and Spark rival heats up

    - PMLiVE

    UniQure’s starts pivotal haemophilia B gene therapy trial

    The treatment could relieve haemophilia B patients from factor IX replacement drugs

    - PMLiVE

    EMA hands UniQure orphan status first in Huntington’s

    The Dutch biotech expects to file the treatment for approval later this year

    - PMLiVE

    FDA grants orphan drug status to UniQure’s Huntington’s Disease treatment

    Becomes first investigational gene therapy to receive ODD for the disease

    - PMLiVE

    UniQure pulls first EU gene therapy

    Decision made due to lack of demand

    - PMLiVE

    uniQure appoints chief executive officer

    Matthew Kapusta takes up the lead role in a permanent capacity

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links